MedTrace Logo

Antiplatelets and Intramyocardial Hemorrhage in STEMI: Incidence and Outcomes

NCT06851325 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 6180

Last updated 2026-03-10

No results posted yet for this study

Summary

The MIRON-PLATELET study is a retrospective, observational multi-center analysis assessing the impact of different antiplatelet therapies on hemorrhagic myocardial infarction (HMI) incidence and outcomes in STEMI patients. Key endpoints include hemorrhagic transformation, MACE, bleeding complications, and 30-day mortality. Findings will offer insights into the safety and clinical implications of antiplatelet therapy in high-risk patients.

Conditions

  • STEMI
  • Acute Myocardial Infarction

Sponsors & Collaborators

  • Rohan Dharmakumar

    lead OTHER

Principal Investigators

  • Rohan Dharmakumar, PhD · Indiana University School of Medicine

  • Keyur P. Vora, MD MS FACC · Indiana University School of Medicine

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-01
Primary Completion
2025-01-30
Completion
2025-02-11

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06851325 on ClinicalTrials.gov